Revenue ($USD): $5,215,000,000 R&D spend: $345,000,000.00 Employees: 19,012 Fiscal year end: 12/31/22 CEO: Deepak Nath, CEO
Smith+Nephew expects 6–7% revenue growth in 2023. “The continued outperformance in Sports Medicine and Advanced Wound Management – representing 60% of our business – has continued,” CEO Deepak Nathrecently said. “In Orthopaedics, our actions to improve product supply and execution have increased our ability to benefit from strong elective procedure volumes.”–CN